美迪西誕愿有您！

2021年轉(zhuǎn)眼即將到尾聲了

感謝大家陪我們又走過了一年的春夏秋冬

也希望在未來日子里

能一直與您相伴~

01

In 2021, more than 70 projects that Medicilon participated in successfully passed clinical trials.

2021年美迪西與客戶合作成功獲得臨床批準(zhǔn)的項目超過70件。

02

Medicilon currently has more than 2,000 scientists and supporting staffs, with 3 R&D centers and a lab space of more than 70,000 square meters.

美迪西現(xiàn)有2000多名員工，3個研發(fā)中心，實驗室面積超過70000平方米。

03

We are committed to enhancing our global service and customer experience with our U.S. Office and European office!

美迪西在北美洲和歐洲等地都有服務(wù)網(wǎng)絡(luò)覆蓋！致力于增強全球化服務(wù)和客戶體驗！

04

We have won a number of heavyweight awards such as "Top 50 Growth Listed Companies", "Top Chinese R&D CRO Enterprises in 2021", “Golden Horse Award-2021 Best Preclinical CRO/CDMO Enterprise”, etc.

榮獲多項重量級獎項——“上市公司成長性50強”、“2021中國研發(fā)CRO企業(yè)20強”、“金馬獎—2021最佳臨床前CRO/CDMO企業(yè)”等。

05

We have established some new service platforms such as PROTAC Drug Discovery Research Platform, Solid Form Screening Platform by Process Department, mRNA Vaccine Bioanalysis Platform, Preclinical Ophthalmic Research Platform, et al.

建立了PROTAC藥物發(fā)現(xiàn)研究平臺、工藝部固體形式篩選平臺、mRNA疫苗生物分析平臺、臨床前眼科研究平臺等多個新型服務(wù)平臺。

06

We have organized several seminars in different cities in China. In addition, we have also exhibited in several worldwide professional academic conferences, such as AACR, DOT, ELRIG, AAPS, etc.

我們在國內(nèi)多個城市組織多次美迪西專題研討會；也參加了多個海外專業(yè)學(xué)術(shù)會議，如AACR, DOT, ELRIG, AAPS等。

春去冬來，日新月異。

走過 2021！迎來 2022！

美迪西感謝您的支持和信任！

美迪西為您準(zhǔn)備了精美的小禮品。